Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Drugs and Chemicals›Chylomicrons
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Chylomicrons

Drugs and Chemicals · NLM MeSH · updated 2026-10-31 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 4 min read

A class of lipoproteins that carry dietary cholesterol and triglycerides from the small intestine to the tissues.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (734 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A class of lipoproteins that carry dietary cholesterol and triglycerides from the small intestine to the tissues. Their density (0.93-1.006 g/ml) is the same as that of very-low-density lipoproteins.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Chylomicron.

Where it fits in the MeSH classification

Broader topics
Lipoproteins
Narrower topics
Chylomicron Remnants

Related concepts

  • Cholesterol
  • Triglycerides
  • Small Intestine
  • Very-Low-Density Lipoproteins

Research landscape

PubMed indexes 3,774 records tagged with the MeSH heading “Chylomicrons” (counts retrieved 2026-10-31). 157 of them (4.2%) were published from 2020 onward, and the busiest period so far is through 1999 with 2,639 records.

Reviews account for 570 records (15.1%) and meta-analyses for 1. Randomized controlled trials number 130 (3.4%) as a share of all records on the topic.

PubMed records by publication periodthrough 1999: 2,639 records; 2000-2009: 596 records; 2010-2019: 382 records; 2020 onward: 157 records2,639through 19995962000-20093822010-20191572020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19992,639
2000-2009596
2010-2019382
2020 onward157
Share of records by publication typeReviews: 15.1 percent; Meta-analyses: 0.0 percent; Randomized controlled trials: 3.4 percentReviews15.1% (570)Meta-analyses0.0% (1)Randomized controlled trials3.4% (130)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 3,774 PubMed records
TypeRecordsShare
Reviews57015.1%
Meta-analyses10.0%
Randomized controlled trials1303.4%

Method: PubMed query "Chylomicrons"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in drugs and chemicals

Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Homozygous missense mutation (G56R) in glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPI-HBP1) in two siblings with fasting chylomicronemia (MIM 144650)
Wang J, Hegele RA
2007Research article
Design not recorded in structured metadata
63cc by
PMID 17883852 · DOI · PMC2039732
Chylomicrons promote intestinal absorption and systemic dissemination of dietary antigen (ovalbumin) in mice
Wang Y, Ghoshal S, Ward M, de Villiers W, Woodward J, Eckhardt E
2009Research article
Design not recorded in structured metadata
57cc by
PMID 20041190 · DOI · PMC2793525
Association of remnant cholesterol with nonalcoholic fatty liver disease: a general population-based study
Zou Y, Lan J, Zhong Y, Yang S, Zhang H, Xie G
2021Research article
Design not recorded in structured metadata
52cc by
PMID 34657611 · DOI · PMC8520640
Resveratrol intervention attenuates chylomicron secretion via repressing intestinal FXR-induced expression of scavenger receptor SR-B1
Pang J, Raka F, Heirali AA, Shao W, Liu D, Gu J, et al.
2023Research article
Design not recorded in structured metadata
46cc by
PMID 37160898 · DOI · PMC10169763

Homozygous missense mutation (G56R) in glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPI-HBP1) in two siblings with fasting chylomicronemia (MIM 144650) [1]

Research article Wang J, Hegele RA · · 2007 · cited 63 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundMice with a deleted Gpihbp1 gene encoding glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPI-HBP1) develop severe chylomicronemia.
Closing excerpt
ConclusionThus, a very rare GPIHBP1 missense mutation appears to be associated with severe hypertriglyceridemia and chylomicronemia.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (157 words)

BackgroundMice with a deleted Gpihbp1 gene encoding glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPI-HBP1) develop severe chylomicronemia. We screened the coding regions of the human homologue--GPIHBP1--from the genomic DNA of 160 unrelated adults with fasting chylomicronemia and plasma triglycerides >10 mmol/L, each of whom had normal sequence of the LPL and APOC2 genes.ResultsOne patient with severe type 5 hyperlipoproteinemia (MIM 144650), fasting chylomicronemia and relapsing pancreatitis resistant to standard therapy was found to be homozygous for a novel GPIHBP1 missense variant, namely G56R. This mutation was absent from the genomes of 600 control subjects and 610 patients with hyperlipidemia. The GPIHBP1 G56 residue has been conserved throughout evolution and the G56R mutation was predicted to have compromised function. Her homozygous brother also had refractory chylomicronemia and relapsing pancreatitis together with early coronary heart disease. G56R heterozygotes in the family had fasting mild hypertriglyceridemia.ConclusionThus, a very rare GPIHBP1 missense mutation appears to be associated with severe hypertriglyceridemia and chylomicronemia.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 17883852 · DOI · PMC2039732

Chylomicrons promote intestinal absorption and systemic dissemination of dietary antigen (ovalbumin) in mice [2]

Research article Wang Y, Ghoshal S, Ward M, de Villiers W, Woodward J, Eckhardt E · · 2009 · cited 57 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundA small fraction of dietary protein survives enzymatic degradation and is absorbed in potentially antigenic form.
Closing excerpt
The fat content of a meal may affect immune responses to dietary antigens by modulating antigen absorption and transport.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (263 words)

BackgroundA small fraction of dietary protein survives enzymatic degradation and is absorbed in potentially antigenic form. This can trigger inflammatory responses in patients with celiac disease or food allergies, but typically induces systemic immunological tolerance (oral tolerance). At present it is not clear how dietary antigens are absorbed. Most food staples, including those with common antigens such as peanuts, eggs, and milk, contain long-chain triglycerides (LCT), which stimulate mesenteric lymph flux and postprandial transport of chylomicrons through mesenteric lymph nodes (MLN) and blood. Most dietary antigens, like ovalbumin (OVA), are emulsifiers, predicting affinity for chylomicrons. We hypothesized that chylomicron formation promotes intestinal absorption and systemic dissemination of dietary antigens.Methodology/principal findingsAbsorption of OVA into MLN and blood was significantly enhanced when OVA was gavaged into fasted mice together with LCT compared with medium-chain triglycerides (MCT), which do not stimulate chylomicron formation. The effect of LCT was blocked by the addition of an inhibitor of chylomicron secretion, Pluronic L-81. Adoptively transferred OVA-specific DO11.10 T-cells proliferated more extensively in peripheral lymph nodes when OVA was gavaged with LCT than with MCT or LCT plus Pluronic L-81, suggesting that dietary OVA is systemically disseminated. Most dietary OVA in plasma was associated with chylomicrons, suggesting that these particles mediate systemic antigen dissemination. Intestinal-epithelial CaCo-2 cells secreted more cell-associated, exogenous OVA when stimulated with oleic-acid than with butyric acid, and the secreted OVA appeared to be associated with chylomicrons.Conclusions/significancePostprandial chylomicron formation profoundly affects absorption and systemic dissemination of dietary antigens. The fat content of a meal may affect immune responses to dietary antigens by modulating antigen absorption and transport.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 20041190 · DOI · PMC2793525

Association of remnant cholesterol with nonalcoholic fatty liver disease: a general population-based study [3]

Research article Zou Y, Lan J, Zhong Y, Yang S, Zhang H, Xie G · · 2021 · cited 52 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundRemnant cholesterol (RC) mediates the progression of coronary artery disease, diabetic complications, hypertension, and chronic kidney disease.
Closing excerpt
(2) Compared with traditional lipid parameters, RC has a better predictive ability for NAFLD in men.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (166 words)

BackgroundRemnant cholesterol (RC) mediates the progression of coronary artery disease, diabetic complications, hypertension, and chronic kidney disease. Limited information is available on the association of RC with nonalcoholic fatty liver disease (NAFLD). This study aimed to explore whether RC can be used to independently evaluate the risk of NAFLD in the general population and to analyze the predictive value of RC for NAFLD.MethodsThe study included 14,251 subjects enrolled in a health screening program. NAFLD was diagnosed by ultrasound, and the association of RC with NAFLD was assessed using the receiver operating characteristic (ROC) curve and logistic regression equation.ResultsSubjects with elevated RC had a significantly higher risk of developing NAFLD after fully adjusting for potential confounding factors (OR 1.77 per SD increase, 95% CI 1.64-1.91, P trendConclusionsThe results obtained from this study indicate that (1) in the general population, RC is independently associated with NAFLD but not with other risk factors. (2) Compared with traditional lipid parameters, RC has a better predictive ability for NAFLD in men.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 34657611 · DOI · PMC8520640

Resveratrol intervention attenuates chylomicron secretion via repressing intestinal FXR-induced expression of scavenger receptor SR-B1 [4]

Research article Pang J, Raka F, Heirali AA, Shao W, Liu D, Gu J, et al. · · 2023 · cited 46 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Two common features of dietary polyphenols have hampered our mechanistic understanding of their beneficial effects for decades: targeting multiple organs and extremely low bioavailability.
Closing excerpt
We conclude that gut microbiome is the primary target of REV-I, and REV-I improves lipid homeostasis at least partially via attenuating FXR-stimulated gut SR-B1 elevation.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (148 words)

Two common features of dietary polyphenols have hampered our mechanistic understanding of their beneficial effects for decades: targeting multiple organs and extremely low bioavailability. We show here that resveratrol intervention (REV-I) in high-fat diet (HFD)-challenged male mice inhibits chylomicron secretion, associated with reduced expression of jejunal but not hepatic scavenger receptor class B type 1 (SR-B1). Intestinal mucosa-specific SR-B1-/- mice on HFD-challenge exhibit improved lipid homeostasis but show virtually no further response to REV-I. SR-B1 expression in Caco-2 cells cannot be repressed by pure resveratrol compound while fecal-microbiota transplantation from mice on REV-I suppresses jejunal SR-B1 in recipient mice. REV-I reduces fecal levels of bile acids and activity of fecal bile-salt hydrolase. In Caco-2 cells, chenodeoxycholic acid treatment stimulates both FXR and SR-B1. We conclude that gut microbiome is the primary target of REV-I, and REV-I improves lipid homeostasis at least partially via attenuating FXR-stimulated gut SR-B1 elevation.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 37160898 · DOI · PMC10169763

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism [5]
    Pepino MY, Kuda O, Samovski D, Abumrad NA · Annu Rev Nutr · 2014 · cited 513 times (Europe PMC)
  • Research article Hepatic uptake of chylomicron remnants [6]
    Cooper AD · J Lipid Res · 1997 · cited 279 times (Europe PMC)
  • Research article Lipoprotein structure and metabolism [7]
    Jackson RL, Morrisett JD, Gotto AM · Physiol Rev · 1976 · cited 249 times (Europe PMC)
  • Research article A proposed model for the assembly of chylomicrons [8]
    Hussain MM · Atherosclerosis · 2000 · cited 195 times (Europe PMC)
  • Research article Lymphatic transport of high-density lipoproteins and chylomicrons [9]
    Randolph GJ, Miller NE · J Clin Invest · 2014 · cited 181 times (Europe PMC)
  • Research article Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score" [10]
    Moulin P, Dufour R, Averna M, Arca M, Cefalù AB, Noto D, et al. · Atherosclerosis · 2018 · cited 165 times (Europe PMC)

References

  1. Wang J, Hegele RA. Homozygous missense mutation (G56R) in glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPI-HBP1) in two siblings with fasting chylomicronemia (MIM 144650). . 2007. PMID 17883852 · DOI · PMC2039732
  2. Wang Y, Ghoshal S, Ward M, de Villiers W, Woodward J, Eckhardt E. Chylomicrons promote intestinal absorption and systemic dissemination of dietary antigen (ovalbumin) in mice. . 2009. PMID 20041190 · DOI · PMC2793525
  3. Zou Y, Lan J, Zhong Y, Yang S, Zhang H, Xie G. Association of remnant cholesterol with nonalcoholic fatty liver disease: a general population-based study. . 2021. PMID 34657611 · DOI · PMC8520640
  4. Pang J, Raka F, Heirali AA, Shao W, Liu D, Gu J, et al.. Resveratrol intervention attenuates chylomicron secretion via repressing intestinal FXR-induced expression of scavenger receptor SR-B1. . 2023. PMID 37160898 · DOI · PMC10169763
  5. Pepino MY, Kuda O, Samovski D, Abumrad NA. Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism. Annu Rev Nutr. 2014. PMID 24850384 · DOI · PMC4329921
  6. Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res. 1997. PMID 9392416 · DOI
  7. Jackson RL, Morrisett JD, Gotto AM. Lipoprotein structure and metabolism. Physiol Rev. 1976. PMID 180553 · DOI
  8. Hussain MM. A proposed model for the assembly of chylomicrons. Atherosclerosis. 2000. PMID 10580165 · DOI
  9. Randolph GJ, Miller NE. Lymphatic transport of high-density lipoproteins and chylomicrons. J Clin Invest. 2014. PMID 24590278 · DOI · PMC3934183
  10. Moulin P, Dufour R, Averna M, Arca M, Cefalù AB, Noto D, et al.. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". Atherosclerosis. 2018. PMID 29980054 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-31.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • Lipoprotein(a)Drugs and Chemicals
  • LipoproteinsDrugs and Chemicals
  • LDL CholesterolDrugs and Chemicals
  • Apolipoproteins ADrugs and Chemicals
  • Apolipoprotein A-IDrugs and Chemicals
  • HDL CholesterolDrugs and Chemicals

All 546 articles in Drugs and Chemicals →

At a glance

3,774
PubMed records on this heading
4%
published since 2020
570
review articles
130
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • Lipoprotein(a)Drugs and Chemicals
  • LipoproteinsDrugs and Chemicals
  • LDL CholesterolDrugs and Chemicals
  • Apolipoproteins ADrugs and Chemicals
  • Apolipoprotein A-IDrugs and Chemicals

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support